Page 478«..1020..477478479480..490500..»

Genetic analysis provides insights into the cause of hydrocephalus, or water on the brain – EurekAlert

Posted: April 19, 2022 at 2:03 am

BOSTON Hydrocephalus, or water on the brain, occurs when the cerebral ventriclesfour interconnected cavities of the brain that are filled with cerebrospinal fluidbecome enlarged, but its cause is unknown in many cases. A better understanding could lead to improved treatments for hydrocephalus, which is the leading reason for brain surgery in children and is associated with neurodevelopmental disability. To provide insights, a team led by investigators at Massachusetts General Hospital (MGH) and Yale University analyzed variations in genetic sequences and gene expression patterns in the brains of patients with congenital hydrocephalus. The research, which is published in Nature Neuroscience, indicates that hydrocephalus does not result from a defect of cerebrospinal fluid plumbing but rather arises because primitive cells in the brain do not behave properly during development.

In patients with hydrocephalus, continued accumulation of fluid dilates the cerebral ventricles, increases pressure in the skull, and compresses the surrounding brain structure. This compression can cause acute symptoms such as vomiting and headache, and even coma or even death. In the long-term, brain compression can lead to neurocognitive issues and neurodevelopmental disabilities in children, even when a medical device called a shunt is surgically placed in the brain.

Neurosurgical shunting of cerebrospinal fluid addresses some consequences of the disease but does not target the underlying mechanisms, says senior author Kristopher T. Kahle, MD, PhD, director of Pediatric Neurosurgery at MGH and director of the Harvard Center for Hydrocephalus and Neurodevelopmental. Knowing the molecular cause of disease could be very helpful towards clinical decision making.

To provide insights, Kahle and his colleagues genetically sequenced cells from 483 children with hydrocephalus and their unaffected parents, using a profiling technology that uncovers gene mutations in patients across the entire genome. By combining the genetic sequence data with gene expression data, the team found that many hydrocephalus-associated genes converge not in fluid circulation components but instead in neuroepithelial cells, which are the earliest stem cells of the brain that arise during the first several weeks of development. These cells go on to generate all of the neurons and support cells of the brain.

This began to hint to us that rather than affecting fluid circulation, hydrocephalus gene mutations may be disrupting the earliest processes of human brain development to cause hydrocephalus, says colead author Phan Q. Duy, an MD/PhD student at Yale University School of Medicine.

The most frequently mutated gene in the studys patientscalled TRIM71codes for a protein that is part of a pathway that regulates the timing of stem cell development. When the investigators bred mice to express TRIM71mutations, the mice developed fetal-onset hydrocephalus similar to human patients. Mechanistically, stem cells in the brains of the Trim71-mutated mice prematurely generated neurons, leading to a deficient pool of stem cells to support brain growth and development. This caused deficient expansion of brain tissue and underdevelopment of the cerebral cortex.

The scientists note that the resulting altered structure of the brain is not capable of holding the pressure exerted by cerebrospinal fluid, and thus the brain deforms and its ventricles passively expand. The site of pathology is therefore not happening in the fluid itself, but rather the vesselor the brain tissuethats holding the fluid, says Duy.

The findings suggest that treatment strategies for hydrocephalus should go beyond draining fluid in the brain. A more nuanced treatment approach may include not only cerebrospinal fluid diversion but also other approaches more tailored towards improving neurodevelopmental function, says Kahle. In the long-term, with continued gene discovery and better understanding of how other gene mutations disrupt brain development to cause hydrocephalus, we may be able to develop drug treatments or even gene therapy to correct the gene mutations months before the birth of patients.

Beyond providing a better understanding hydrocephalus, this work may offer additional insights into other pediatric brain disorders. In fact, ventricular dilation is a common feature in developmental neuropsychiatric diseases such as autism and schizophrenia, and many of the processes involved with hydrocephalus may also be relevant for other structural brain malformations.

This work was supported by the National Institutes of Health, Rudi Schulte Institute, and the Hydrocephalus Association.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Instituteconducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in theU.S. News & World Reportlist of "Americas Best Hospitals." MGH is a founding member of the Mass General Brigham health care system.

Nature Neuroscience

Impaired neurogenesis alters brain biomechanics in a neuroprogenitor-based genetic subtype of congenital hydrocephalus

4-Apr-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original post:
Genetic analysis provides insights into the cause of hydrocephalus, or water on the brain - EurekAlert

Posted in Gene therapy | Comments Off on Genetic analysis provides insights into the cause of hydrocephalus, or water on the brain – EurekAlert

Kaleido Biosciences is winding up operations as bluebird bio and other biotech firms announce layoffs – BioPharma-Reporter.com

Posted: April 19, 2022 at 2:03 am

The cessation of operations does not come as a complete surprise.The biotech, in an earnings call in November last year, had flagged that it would run out of cash at some point in the second quarter.

According to Fridays SEC filing, a strategic process to find a solution, with Kaleido having engaged professional advisors, did not result in the identification of any viable transactions.

The company had already shrunk its workforce, back in January this year, following its decision to halt a planned phase 2 trial in chronic obstructive pulmonary disease (COPD) and to end its agreement with the COPD Foundation.

Last year, Kaleido received a warning letter from the US Food and Drug Administration (FDA) over a program it was running with its COPD drug in COVID-19 studies. The FDA said the company failed to seek an Investigational New Drug (IND) application for the study using its COPD therapy, KB109. Kaleido argued that it investigated KB109 as a food rather than a drug and did not need to be authorized under an IND.

Kaleidos closure comes as several other biotechs are experiencing a cash crunch and as investor sentiment in the sector would seem to be waning, for now. Biogen, bluebird bio, and Taysha, among others, have announced layoffs of late.

Last Tuesday, gene therapy player, bluebird Bio, reported it was cutting staffing numbers by nearly 30%, with it targeting up to US$160m in cost savings over the next two years. The restructuring drive is expected to lower the companys 2022 cash burn to less than $340m, with a 35 to 40% reduction in operating costs anticipated by year-end 2022.

In March, the biotech had warned that its financial position raised substantial doubt about its ability to continue as a going concern.

Bluebird bio has faced a number of unexpected hurdles recently in its bid to get approval for its investigational therapies.

In December 2021, the FDA paused a trial of its gene therapy candidate - lovo-cel - for sickle cell disease patients under the age of 18, while, in January this year, the US regulatory body extended the review period for the biologics licensing applications (BLA) for bluebird's lentiviral vector gene therapies betibeglogene autotemcel (beti-cel) for beta-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD).

CEO Andrew Obenshain, on a call last week, noted the combination of those setbacks plus a tough biotech market has taken some traditional financing off the table in the near term. Were optimistic that these options may be viable sources of funding in the future, but we recognize the need for action today.

Bluebird said it now intends to sharpen its focus on near-term catalysts, including anticipated FDA approvals for both of its gene therapies and that it also expects to submit a BLA for lovo-cel in Q1 2023.

The company outlined how it is intending to maintain targeted research efforts focused on in vivo lentiviral vector (LVV) gene therapies and that it will deprioritize direct investments in reduced toxicity conditioning and cryopreserved apheresis.

Texas based Taysha, a biotech also focused on gene therapies, announced a 35% reduction in employees at the end of March. It has narrowed its R&D pipeline to two programs: giant axonal neuropathy (GAN) and Rett syndrome.

Activities for other ongoing clinical programs will be minimized and all additional research and development will be paused to increase operational focus and efficiency, it added.

Visit link:
Kaleido Biosciences is winding up operations as bluebird bio and other biotech firms announce layoffs - BioPharma-Reporter.com

Posted in Gene therapy | Comments Off on Kaleido Biosciences is winding up operations as bluebird bio and other biotech firms announce layoffs – BioPharma-Reporter.com

Sung to lead cancer institute; Bankston wins fellowship – ASBMB Today

Posted: April 19, 2022 at 2:02 am

Sung takes over at San Antonio cancer institute

Patrick Sung, a professor, interim department chair and associate dean for research at the University of Texas Health Science Center at San Antonio's Long School of Medicine, has taken on another leadership role there. On March 1, he became the new director of the Greehey Children's Cancer Research Institute. He succeeds interim director Manjeet Rao and former director Peter Houghton.

Patrick Sung

The institute, founded in 2004, is a group of 18 labs doing research focused on topics related to pediatric cancers, including cancer genomics, DNA repair, tumor biology and drug development. Research in Sungs lab, which is part of the institute, focuses on DNA damage repair. He studies homologous recombination as a mechanism for repairing double-stranded DNA breaks, focusing on the mechanism of the recombinase Rad51. His lab is known for recapitulating double-stranded DNA repair in vitro. Failure of such repair can lead to chromosomal rearrangements that drive the development of cancer; at the same time, cancer cells are unusually adept at repairing DNA damage. Several years ago, Sungs lab found that Rad51 interacts with the well-known BRCA tumor suppressor proteins, suggesting new insights into how BRCA proteins suppress tumor formation.

Sung earned his Doctor of Philosophy degree in biochemistry at the University of Oxford in 1985. He came to the U.S. for a postdoc at the University of Rochester. After starting his faculty career at the University of Texas Medical Branch in Galveston, he worked as an associate professor at UT Health San Antonio before taking a position at Yale in 2003, in the department of molecular biophysics and biochemistry, which he later chaired. He was recruited back to the University of Texas in 2019 as a professor.

Sung has been an associate editor of the Journal of Biological Chemistry since 2014. He also is on the editorial board of the journal Genes and Development and formerly served on the editorial board of the journal Molecular & Cellular Biology.

Adriana Bankston, a legislative analyst for the University of California, has received a 2022 fellowship from Advancing Research Impact in Society, or ARIS, a program supported by the National Science Foundation.

Adriana Bankston

This award, shared with the University of California, Irvine's Harinder Singh, will support a program for training in science policy. The project, titled "Developing the next generation workforce through science policy as a bridge between science and society," will use insights from a course that Bankston and Singh taught at Irvine to develop an educational toolkit for universities and to build a community of practice in science policy and advocacy.

Bankston received her Ph.D. in biochemistry and cell and developmental biology at Emory University and was a postdoctoral researcher at the University of Louisville before becoming a policy and advocacy fellow at the Society for Neuroscience. Today, in addition to her position at UC, she works on numerous initiatives as chief executive officer and managing publisher of the Journal of Science Policy and Governance, and as a research investigator with the STEM Advocacy Institute. In February, she was part of a panel discussion hosted by the National Academies of Science, Engineering and Medicine's strategic council for research excellence, integrity and trust. She is also an ASBMB Today contributor.

The Center for Advancing Research Impact in Society is a project to improve public engagement with science and diversify the research workforce. Its fellows, selected annually, work on projects that synthesize research to help scientists achieve these goals.

Read more:
Sung to lead cancer institute; Bankston wins fellowship - ASBMB Today

Posted in Texas Stem Cells | Comments Off on Sung to lead cancer institute; Bankston wins fellowship – ASBMB Today

Regenerative medicine will be mainstream in 10 years, says spine CEO – Becker’s ASC Review

Posted: April 19, 2022 at 2:00 am

New technologies and procedures are often met with pushback initially.

Thomas Schuler, MD, founder and CEO of the Virginia Spine Institute in Reston, joined "Becker's ASC Review Podcast" to talk about how the adoption of interventional medicine could change in the near future.

Note: This is an edited excerpt. Listen to the full podcast episode here.

Question: Over the next five years, what do you think will be different in the physician practice landscape, and what do you think will be the same?

Dr. Thomas Schuler: When you look back over medicine at things that have stood the test of time, X-rays have been around over a hundred years, and yet they're still essential. If you break an arm, you get a cast put on it to get the bone to heal, and you use the body's own biology to heal. Casting has been around for over a hundred years.

What's really exciting about the future is we're using people's own biology to heal. What I mean is, we're using regenerative medicine to heal injured discs, injured ligaments and restore people back to function without surgery, using their own biology.

There's a lot of naysayers who feel regenerative medicine hasn't been proven, but we've been doing this for over a decade and seen unbelievable change in how we manage patients.

We don't want to do a five-level fusion to treat back pain, but we do regenerative medicine where we take their marrow, concentrate it down, inject it into their disc, and now they're back skiing and golfing and doing everything.

So I believe that over the next five to 10 years, the rest of the medical community will finally wake up and understand what an unbelievable improvement it is to use the patient's own biology, not an off-the-shelf product.

Here is the original post:
Regenerative medicine will be mainstream in 10 years, says spine CEO - Becker's ASC Review

Posted in Regenerative Medicine | Comments Off on Regenerative medicine will be mainstream in 10 years, says spine CEO – Becker’s ASC Review

UI professor to research collaborative regenerative medicine in Ireland – UI The Daily Iowan

Posted: April 19, 2022 at 2:00 am

James Ankrum, a University of Iowa biomedical engineering professor, will bring his expertise in cell biology to a world-renowned research lab in Dublin.

A University of Iowa professor will travel to Ireland for a collaborative effort aimed at advancing research in the field of regenerative medicine.

James Ankrum, UI associate professor of biomedical engineering, was one of over 400 professionals, artists, and scholars who received the competitive Fulbright Scholar Award to fund his journey.

He said his work with the Royal College of Surgeons in Ireland will be an ongoing effort that combines its renowned tissue engineering program with his cell biology expertise to tailor the cells of the body for ailment therapy and relief.

This isnt just a six-month [thing], where we work together for a semester, Ankrum said. The plan is that were going to lay the foundation for a collaborative project that will last for years to come. Thats really the goal is to put in the work so that weve got a great base foundation.

Ankrums trip, he said, looks to research replicating the bodys natural signals to help those with chronic wounds.

Chronic wounds are often seen in individuals with diabetes, as well as military personnel, who are facing increasingly complex injuries from big explosions.

If we can learn how the cells in the body communicate with each other to heal rather than scar, Ankrum said. We can actually mimic those properties, those signals, those communication tactics and employ them as medicines.

Ankrums research with his Irish colleagues will continue to further their research as well.

He said the Royal College of Surgeons combines gene therapies with biomaterial scaffolding, the surface where cells are encouraged to grow.

The scaffolding has gene therapies embedded in the scaffolding and when cells migrate onto the surface of that scaffolding, the cells begin to receive the signals to reproduce.

Ankrums research allows larger-scale research into how to maximize the therapeutic aspect of the structure, Ankrum said.

The ultimate goal of research on regenerative medicine, Ankrum said, is to help reverse the effects of disease and restore the functionality of tissues that have devolved.

With heart disease, for example, tissues become diseased and are failing and no longer function as they once did, Ankrum said. Can we actually turn back the clock by understanding, What are the signals and cues and necessary players to restore true function?

Kristan Worthington, member of the Member Institute for Vision Research and UI assistant professor of biomedical engineering, focuses her research on regenerative medicine within the human retina, the part of the eye responsible for sensing light.

Lots of older people experience vision loss that is, at this point, irreversible, Worthington said. That really impacts someones quality of life in a very big way.

Worthingtons latter research focus mirrors Ankrums focus in Ireland with the biometric scaffolding.

She said regenerative research is important because researchers are still far away from being able to mimic the human bodys ability to stimulate tissue.

For me, its a lifelong pursuit of understanding and being able to modulate the human body to increase quality of life and improve the experience of humans all over the world, Worthington said.

Ankrum said regenerative medicine helps target individual suffering and alleviate it.

Being able to offer [veterans] something that isnt just, Heres pain medication, but something that can actually restore their body to what it once was before they were deployed, that plays into it, Ankrum said.

Read the original:
UI professor to research collaborative regenerative medicine in Ireland - UI The Daily Iowan

Posted in Regenerative Medicine | Comments Off on UI professor to research collaborative regenerative medicine in Ireland – UI The Daily Iowan

The Advanced Pain-Free Treatment as Promoted by QC Kinetix (Murfreesboro) Regenerative Medicine in Murfreesboro, Tennesee – Yahoo Finance

Posted: April 19, 2022 at 2:00 am

MURFREESBORO, TN - (NewMediaWire) - April 15, 2022 - via QC Kinetix -- QC Kinetix (Murfreesboro) has unveiled a series of therapies designed to reduce pain, improve range of motion, and enhance the overall quality of life. Their medical team carefully engineers the biologic therapies to provide lasting relief against joint pain and musculoskeletal injuries. For patients seeking regenerative medicine to calm the throes of chronic pain, the clinic offers zero obligation consultation with a medical provider who will explain the treatment and determine the patient's eligibility.

Chronic pain patients searching for effective regenerative medical solutions in Murfreesboro, TN, will be hard-pressed to choose QC Kinetix (Murfreesboro) as their next stop. The clinic has an experienced medical team ready to give their best to help patients overcome persistent pain and its long-term effects. These natural treatment protocols target knee pain, pain due to sports injuries, elbow pain, and shoulder pain. In addition, patients with sports injuries will readily find experts ready to attend to conditions like golfer's elbow, tennis elbow, and torn rotator cuff. Immediate intervention by QC Kinetix (Murfreesboro) providers will help the patient forgo the uncomfortable knee brace and expensive surgery. It also helps to know that the clinic is top-rated in the Murfreesboro regenerative medicine circles.

The clinic is part of QC Kinetix, a premier regenerative medicine group on a mission to improve patients' overall quality of life by easing their worries about pain and musculoskeletal injuries. Patients are also visiting the QC Kinetix (Murfreesboro) clinic due to QC Kinetix's nationwide network and personalized, concierge-level services touted to be among the very best. The non-invasive treatments also promise long-lasting results, which translates to reduced pain, improved body function and enhanced quality of life. Patients booked at the pain clinic will have their condition carefully assessed before a fitting regenerative therapy plan is created to treat the chronic pain and associated symptoms.

With as many as 80 million Americans suffering from pain, the emergence of regenerative medicine is welcome news for many people. The alternative treatment to surgery has been found effective in treating and managing chronic pain and sports injuries. It works at the cellular level by sparking organic self-repair and restoration of damaged or degenerated body tissues. For patients suffering from pain due to arthritis, regenerative medicine takes away the suffering and replaces it with long-term relief. The state-of-the-art pain control clinic in Murfreesboro, TN, provides treatment with the help of highly experienced providers trusted to administer safe and efficient biologic therapies. Joint pain patients are also invited for a dose of the breakthrough treatment targeting the fingers, toes, ankles, shoulder, wrist, and other joint areas.

QC Kinetix (Murfreesboro) is fully aware of the perils of chronic pain and its net negative impact on depriving patients of the joys of enjoying an improved quality of life. The immediate effects of chronic pain are limited mobility and the inability to perform normal day-to-day activities. To ensure transformative treatment, the providers always target the root cause of the problem before applying the non-invasive treatment protocols to overcome pain and its symptoms once and for all. People who are busy or those seeking to get on with their lives will love the idea that treatment with regenerative medicine carries little to no downtime. Leading the team of providers at the QC Kinetix (Murfreesboro) clinic are Erin Bryan, PA, and Dr. Morgan Keningston, MD, who has been working in the regenerative medicine sphere for five years. She has been a primary-care outpatient physician for eight years and an in-house hospitalist at Williamson Medical Clinic for four years.

Erin Bryan, PA, is an NCCPA-certified Physician Assistant who focuses on delivering quality care to all chronic pain patients. She holds a Bachelor's Degree in Science and a minor in Psychology. The clinic's website has testimonials that show real-life experiences and sentiments of patients treated under the QC Kinetix nationwide network. A YouTube testimonial by a severe knee pain patient shows how he could not run a full half marathon but managed to return to full racing after undergoing treatment. To learn more about their Murfreesboro office, check out their website for first-hand information about the biologic therapies, medical providers, amenities, and more personal accounts of patients who have undergone treatment.

To contact the biologic therapy medical providers, call (615) 249-4024 or visit the clinic that is strategically stationed at 1747 Medical Center Parkway, Suite 110, Murfreesboro, Tennessee, 37129. The cost of treatment using regenerative medicine is revealed during the round of consultation. Their in-house providers will disclose the actual cost after determining the patient's exact treatment, as they strive to provide affordable treatment regimens. A major plus about regenerative medicine is the correspondingly low downtime or recovery time of six to nine months after the safe and effective treatment is administered.

Source: GetFeatured

Company Name: QC Kinetix (Murfreesboro)

Contact Person: Scott Hoots

Phone: (615) 249-4024

Address: 1747 Medical Center Parkway, Suite 110

City: Murfreesboro

State: TN

Postal Code: 37129

Country: US

See the rest here:
The Advanced Pain-Free Treatment as Promoted by QC Kinetix (Murfreesboro) Regenerative Medicine in Murfreesboro, Tennesee - Yahoo Finance

Posted in Regenerative Medicine | Comments Off on The Advanced Pain-Free Treatment as Promoted by QC Kinetix (Murfreesboro) Regenerative Medicine in Murfreesboro, Tennesee – Yahoo Finance

Hearing Loss Can Be Reversed With New Regenerative Therapy, Say MIT Scientists – IFLScience

Posted: April 19, 2022 at 2:00 am

If you know at least two random people, then chances are you know somebody with somedegree of hearing loss. For many of those people, its just a minor thing an annoying reason to turn the TV volume up. But for others, it candrastically impact quality of life no longer able to make out what loved ones are saying, cut off from the music and social lifethey used to enjoy, and maybe living with endless ringing and buzzing in its place.

Atherapy that could reverse hearing loss would be life-changing for millions and thats what biotechnology company Frequency Therapeutics, a spinout company from MIT, says theyve created. Not a hearing aid, not an implant, but a new drug that can give people their hearing back.

Hearing is such an important sense; it connects people to their community and cultivates a sense of identity, said Jeff Karp, Frequency Therapeutics co-founder and professor of anesthesia at Brigham and Womens Hospital, in a statement. I think the potential to restore hearing will have enormous impact on society.

So how does this potential cure for hearing loss work? Its kind of amazing: the drug stimulates progenitor cells a descendent of stem cells that live in the inner ear to start new making hair cells.

Making your ears more hirsute may not sound like the obvious cure for hearing loss, but it actually makes a lot of sense. We sometimes think of hearing as finishing when the noise hits our eardrum, but thats only half of the story: after that, the vibrations from the sound waves move on to the ossicles the three smallest bones in your body. These tiny bones are really neat: they basically act like a hammer hitting a gong thats next to a loudspeaker. Except teeny.

That loudspeaker, aka the cochlea, is where the hair cells come in. Its a hollow bone in the shape of a spiral the name actually means snail shell filled with fluid. When that fluid is moved by the vibrations from the noise, up to 15,000 hair cells in the cochlea pick it up, and theyre what finally send the signals to the auditory nerve so that we can hear the original noise.

So: no hair cells, no hearing. The problem is, those cells are very fragile they can be damaged by certain illnesses and medications, or even just too many loud noises. And once theyre gone, they dont come back.

Until now, apparently.

Some of these people [in the trials] couldnt hear for 30 years, and for the first time they said they could go into a crowded restaurant and hear what their children were saying, said co-founder and MIT Institute Professor Robert Langer. Its so meaningful to them. Obviously more needs to be done, but just the fact that you can help a small group of people is really impressive to me.

Frequency Therapeutics says theyve already given the treatment to more than 200 people, and seen significant improvements in patients hearing in three out of four clinical trials. The therapy is long-lasting hearing has been improved for nearly two years in some cases and it comes in the form of a single injection into the inner ear, making it much simpler and quicker than alternatives like gene therapy.

I wouldn't be surprised if in 10 or 15 years, because of the resources being put into this space and the incredible science being done, we can get to the point where [reversing hearing loss] would be similar to Lasik surgery, where you're in and out in an hour or two and you can completely restore your vision, Karp says. I think we'll see the same thing for hearing loss.

However,perhaps the most tantalizing aspect of this new therapy is its future potential.

Tissues throughout your body contain progenitor cells, so we see a huge range of applications, explained Frequency co-founder and Chief Scientific Officer Chris Loose. We believe this is the future of regenerative medicine.

When we were conceiving of this project, we meant for it to be a platform that could be broadly applicable to multiple tissues, added Karp.

To me its the tip of the iceberg in terms of what can be done by taking small molecules and controlling local biology.

Read the original:
Hearing Loss Can Be Reversed With New Regenerative Therapy, Say MIT Scientists - IFLScience

Posted in Regenerative Medicine | Comments Off on Hearing Loss Can Be Reversed With New Regenerative Therapy, Say MIT Scientists – IFLScience

FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS – PR Newswire

Posted: April 19, 2022 at 2:00 am

AUSTIN, Texas, April 12, 2022 /PRNewswire/ -- Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle (EV) platform drug technology, announced that the U.S. Food and Drug Administration (FDA) has awarded their EV drug product ExoFlo with a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The RMAT program is designed to expedite the approval of promising regenerative medical products in the US that demonstrate clinical evidence indicating the ability to address an unmet medical need for a serious life-threatening disease or condition. Under the RMAT designation, the FDA provides intensive guidance on drug development and post-market requirements through early and frequent interactions. Additionally, an RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA).

"After intensively reviewing our preclinical data, manufacturing processes, and clinical data from our Phase II multicenter, double blinded, placebo controlled randomized clinical trial, the FDA has recognized ExoFlo as a lifesaving treatment for patients suffering from Acute Respiratory Distress Syndrome (ARDS) due to severe or critical COVID-19," said Mark Adams, Chief Executive Officer. "The additional attention, resources, and regulatory benefits provided by an RMAT designation demonstrate that the FDA views ExoFlo as a product that can significantly enhance the standard of care for the thousands still dying from ARDS every week in the US," he said.

"We are very pleased that the FDA has recognized the lifesaving potential of our platform drug technology ExoFlo. The RMAT has provided a pathway to expedite our drug development to achieve a BLA in the shortest possible time," said Joe Schmidt, President. "I am very proud of our team. Everyone has been working around the clock for years in our mission to save human lives taken by a disease that lacks treatment options, both in the US and abroad. We are grateful for the opportunity to accelerate development of ExoFlo under the RMAT designation as it leads us closer to our goal of bringing our life saving drug to patients who desperately need it."

ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product. These nanosized EVs deliver thousands of signals in the form of regulatory proteins, microRNA, and messenger RNA to cells in the body, harnessing the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity and limitations of scalability associated with MSC transplantation. ExoFlo is produced using a proprietary EV platform technology by Direct Biologics, LLC.

Physicians can learn more and may request information on becoming a study site at clinicaltrials.gov. For more information on Direct Biologics and regenerative medicine, visit: https://directbiologics.com.

About Direct BiologicsDirect Biologics, LLC, is headquartered in Austin, Texas, with an R&D facility located at the University of California, and an Operations and Order Fulfillment Center located in San Antonio, Texas. Direct Biologics is a market-leading innovator and cGMP manufacturer of regenerative medical products, including a robust EV platform technology. Direct Biologics' management team holds extensive collective experience in biologics research, development, and commercialization, making the Company a leader in the evolving segment of next generation regenerative biotherapeutics. Direct Biologics has obtained and is pursuing multiple additional clinical indications for ExoFlo through the FDA's investigational new drug (IND) process. For more information visit http://www.directbiologics.com.

SOURCE Direct Biologics

Read this article:
FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS - PR Newswire

Posted in Regenerative Medicine | Comments Off on FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS – PR Newswire

What is Australian govt doing to boost stem cell research? – Kalkine Media

Posted: April 19, 2022 at 2:00 am

There are different types of cells designed for a specific job in the human body. To cite a few, white blood cells help in defence, while red blood cells carry oxygen. Stem cells are exceptional cells that possess unique regeneration abilities. They can also create more specialised kinds of cells that can replace the cells lost by the human body either through an injury or in the daily wear and tear process.

Do read: Living Cell (ASX: LCT) surges over 14% on clinical trial for Parkinson's disease

In a broader category, there are generally two types of stem cells

Advances in stem cell research have laid a strong foundation for regenerative medicine. Stem cells have become a frontier of regenerative medicine due to their unlimited self-renewal and differentiation potential.

Regenerative medicine is a division of medicine that works on rebuilding tissues or organs to resume their functions in human beings affected by several injuries or chronic diseases. It has the capability to treat complicated medical conditions that are otherwise impossible by conventional methods.

Image source: German101 | Megapixl.com

Stem cell therapy has proven its potential in treating blood disorders including leukaemia, Hodgkins disease, and non-Hodgkins lymphoma. Stem cells also hold the possibility to cure many other types of complicated medical conditions, boosting hopes for the treatment of incurable diseases.

Also read: Precision medicine: All you need to know

Stem cell research in Australia

Australian scientists have made a considerable contribution to the knowledge about stem cells found in human beings and their potential, particularly in adult stem cells.

Both private and government institutions/firms are involved in stem cell research in the nation. These efforts got a further boost when the National Stem Cell Centre was established in 2002.

Govt pours AU$25 million into stem cell research

According to a report by the Australian Department of Health, the Australian government has provided grants worth AU$25 million for enhancing Australia-led stem cell research. Starting from 2021-22, the fund will be available for over five years through two funding streams.

Stream 1 up to AU$15 million: for developing treatments based on novel stem-cell by large scale multidisciplinary teams.

Stream 2 up to AU$10 million: for large scale multidisciplinary teams. This will be directed towards examination and pre-clinical assessment of novel treatments that deploy human tissues made from stem cells.

Stem Cell Therapies Mission

The Australian government has established the Stem Cell Therapies Mission intending to develop innovative, safe, and efficient treatments to enhance the health conditions of people. It has teamed up with patients and carers and is investing an amount of AU$150 million for the mission.

Also read: How to boost your immunity and maintain distance from pathogens?

See the original post here:
What is Australian govt doing to boost stem cell research? - Kalkine Media

Posted in Regenerative Medicine | Comments Off on What is Australian govt doing to boost stem cell research? – Kalkine Media

World Liver Day 2022: Expert answers frequently asked questions – The Indian Express

Posted: April 19, 2022 at 2:00 am

Liver is the second largest and one of the most complex organs in the body, yet awareness regarding liver diseases continues to be low. This is why, World Liver Day is observed on April 19 every year to create awareness about diseases related to the liver. Dr Prashant Vilas Bhangui, associate director, Institute of Liver Transplantation and Regenerative Medicine, Medanta Hospital, Gurugram answers some frequently asked questions related to liver diseases.

What is cirrhosis of the liver?

Liver disease initially starts off with fatty liver (where there is an accumulation of excess fat in the liver). This then progresses to fibrosis of the liver which leads to stiffness, and ultimately end-stage liver disease or cirrhosis, the expert added.

Causes

The most common causes of liver disease are viral hepatitis i.e., hepatitis C and hepatitis E, excessive consumption of alcohol, and an unhealthy lifestyle that may cause obesity. A patient who drinks alcohol for prolonged periods of time in substantial quantity ultimately develops cirrhosis. Additionally, people who are overweight, lead an unhealthy lifestyle, have unhealthy diet, lack physical activity, and suffer from co-morbid conditions like diabetes, hypertension, thyroid disorders, and abnormal cholesterol levels are at a risk of developing non-alcoholic fatty liver disease (NAFLD), which progresses to cirrhosis. NAFLD has become a leading cause of cirrhosis of the liver in many countries. Other congenital causes of cirrhosis in children are biliary atresia, metabolic disease of the liver. Some rare causes include autoimmune hepatitis, Wilsons disease, and hemochromatosis.

Symptoms

Initially, a patient may experience constant lethargy, fatigability, swelling of the feet after walking, jaundice, fluid in the abdomen, episodes of bleeding, portal hypertension in the later stage leading to vomiting of blood, blood in stools, internal bleeding. Liver failure also affects other organs like kidney, and even leads to memory loss, and drowsiness.

Diagnosis

If someone has a genetic pre-disposition to cirrhosis and has symptoms of liver disease or is suffering from viral hepatitis for a long period of time, they must get some blood tests, liver function tests, abdominal ultrasound, CT scan, and endoscopy done to understand the stage of cirrhosis they are at.

Stages

Compensated cirrhosis The liver functions get damaged to a great extent; however, the body somehow copes with that liver function, sometimes to an extent of 50-60 per cent.

Decompensated cirrhosis When the liver damage becomes more than about 70-80 per cent. The patients gets symptoms like swelling of the feet, accumulation of fluids in the abdomen, bleeding tendencies, and effects on other organs e.g., on kidneys and brain.

Can cirrhosis be cured?

Once the liver reaches the stage of cirrhosis, the disease becomes irreversible. Fatty liver and early stage of liver fibrosis can be cured through medications along with diet control, understanding causes, and taking proper actions to reverse the condition. Patients at the stage of cirrhosis are highly recommended medical therapies, to support the liver and prevent the progression of the disease. The doctor, based on the CTP (Child-Turcotte-Pugh) score, and other additional scores, determines the treatment procedure i.e., medical treatment or to undergo liver transplantation.

Prevention tips

There are some high-risk individuals who may get exposed to hepatitis B and C like healthcare workers, and patients having blood transfusions, hould be extra vigilant and take extra precautions. The viral markers used to identify a range of Hepatitis B, C, and other viral infections needed to be checked at regular intervals. Experts suggest undergoing an annual check-up including a liver function test, and an ultrasound after the age of 45-50, blood tests are done for early detection, especially for the people who are diabetic, hypertensive, and have thyroid disorders.

People should avoid excessive consumption of alcohol, have a healthy diet, avoid fried and junk food, exercise regularly, avoiding smoking, etc.

Is it possible to cleanse the liver? Is it a myth?

Its more of a myth than reality. There is nothing called cleansing a liver. One can take effective measures including liver-friendly juices, staying hydrated, and eating healthy foods that help in maintaining the healthy liver.

For more lifestyle news, follow us on Instagram | Twitter | Facebook and dont miss out on the latest updates!

Original post:
World Liver Day 2022: Expert answers frequently asked questions - The Indian Express

Posted in Regenerative Medicine | Comments Off on World Liver Day 2022: Expert answers frequently asked questions – The Indian Express

Page 478«..1020..477478479480..490500..»